It was a pleasure to meet with Prof. John Walton Sanders (Wake Forest School of Medicine and the Hefner VAMC, Winston-Salem, NC, USA) to discuss the a subset analysis of the Phase 3 FURI study investigating the outcomes of patients with Candida bone and joint infections when treated with ibrexafungerp.
The abstract entitled: ‘Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI)’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
- What are the aims, and design of the FURI Phase III study and the subsequent subset analysis? (0:13)
- What are the eligibility criteria of the study? (1:16)
- What were the findings of the subset analysis investigating ibrexafungerp for Candida osteoarticular infections? (2:02)
- What will be the next steps towards regulatory approval of ibrexafungerp in this indication? (3:37)
Disclosures: John Sanders has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
Share this Video
Related Videos In Bacterial and Fungal Infections
Jinhee Jo, IDWeek 2021: Global Surveillance of Clostridioides difficile
It was a pleasure to meet with Dr Jinhee Jo (Department of Pharmacy Practice and Translational Research, University of Houston, Houston, TX, USA) to discuss her study investigating the understanding of how C. Difficile is transmitted, and who it affects. The abstract entitled: ‘Global Surveillance of Clostridioides difficile Demonstrates High Prevalence in Non-Healthcare Settings’ was […]
Kevin Garey, IDWeek 2021: Health-related Quality of Life Findings from the ECOSPOR Phase 3 Trial
It was a pleasure to meet with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the results from the ECOSPOR phase 3 trial, and how SER-109 impacts patients’ health-related quality of life. Watch Part 1 of this interview here. The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic […]
Kevin Garey, IDWeek 2021: Limitations of Current Treatment Approaches for Recurrent C difficile Infections
We had the great pleasure of meeting with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the health burden of C difficile infections, and the limitations of current treatment approaches. Watch Part 2 of the interview here. The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic SER-109 on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!